XOMA Co. (NASDAQ:XOMA) CIO Bradley Sitko Acquires 4,134 Shares

XOMA Co. (NASDAQ:XOMA) CIO Bradley Sitko acquired 4,134 shares of the firm’s stock in a transaction dated Friday, March 21st. The stock was bought at an average cost of $23.89 per share, for a total transaction of $98,761.26. Following the purchase, the executive now directly owns 10,484 shares of the company’s stock, valued at approximately $250,462.76. This trade represents a 65.10 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Bradley Sitko also recently made the following trade(s):

• On Wednesday, January 8th, Bradley Sitko bought 313 shares of XOMA stock. The stock was purchased at an average cost of $25.60 per share, with a total value of $8,012.80.
• On Tuesday, December 31st, Bradley Sitko purchased 300 shares of XOMA stock. The shares were purchased at an average cost of $25.90 per share, for a total transaction of $7,770.00.

XOMA Trading Down 0.9 %

XOMA stock opened at $20.74 on Wednesday. XOMA Co. has a 1 year low of $19.92 and a 1 year high of $35.00. The firm’s 50 day moving average price is $24.16 and its 200-day moving average price is $27.03. The company has a debt-to-equity ratio of 1.28, a current ratio of 7.52 and a quick ratio of 7.52. The stock has a market cap of $248.44 million, a P/E ratio of -5.96 and a beta of 1.00.

XOMA (NASDAQ:XOMA) last announced its quarterly earnings results on Monday, March 17th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.17). XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. The company had revenue of $8.70 million during the quarter, compared to the consensus estimate of $8.75 million. On average, equities analysts predict that XOMA Co. will post -1.41 earnings per share for the current fiscal year.

Institutional Investors Weigh In On XOMA

A number of hedge funds have recently made changes to their positions in XOMA. BNP Paribas Financial Markets increased its stake in XOMA by 95.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 795 shares during the last quarter. New York State Common Retirement Fund grew its holdings in shares of XOMA by 51.2% in the fourth quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company’s stock valued at $62,000 after purchasing an additional 800 shares in the last quarter. Wells Fargo & Company MN increased its position in XOMA by 38.0% in the fourth quarter. Wells Fargo & Company MN now owns 4,300 shares of the biotechnology company’s stock worth $113,000 after purchasing an additional 1,183 shares during the last quarter. Bank of America Corp DE increased its position in XOMA by 34.7% in the fourth quarter. Bank of America Corp DE now owns 7,796 shares of the biotechnology company’s stock worth $205,000 after purchasing an additional 2,009 shares during the last quarter. Finally, Los Angeles Capital Management LLC purchased a new stake in XOMA during the fourth quarter valued at $206,000. 95.92% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. HC Wainwright restated a “buy” rating and set a $104.00 price objective on shares of XOMA in a research report on Wednesday, March 19th. StockNews.com raised XOMA from a “sell” rating to a “hold” rating in a report on Friday, March 21st.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.